Nerandomilast and mycophenolate for non-IPF pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether combining two medications—nerandomilast (a new anti-inflammatory drug) and mycophenolate (an immunosuppressant you may already be taking)—can safely slow lung scarring in people with pulmonary fibrosis other than IPF. The goal is to help doctors decide if this combination is right for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pulmonary fibrosis (scarring of the lungs) confirmed by CT scan, but NOT idiopathic pulmonary fibrosis (IPF)
- Your CT scan shows at least 10% lung scarring, taken within the past year
- You've been taking a stable dose of mycophenolate for at least 3 months (at least 1,500mg daily)
- Your lung function tests show FVC ≥ 45% and DLCO ≥ 25% (measured within 3 months)
- You've been clinically stable for the past 6 weeks without needing hospitalization or new steroid treatment
- You are not taking certain other strong immunosuppressive drugs (azathioprine, cyclophosphamide, rituximab, tocilizumab) within the past 3 months, and haven't taken pirfenidone or nintedanib within 6 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.